All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 78 points (-0.5%) at 16,015 as of Monday, Jan. 25, 2016, 11:55 AM ET. The NYSE advances/declines ratio sits at 648 issues advancing vs. 2,316 declining with 132 unchanged.

The Drugs industry currently sits up 0.7% versus the S&P 500, which is down 0.6%. Top gainers within the industry include

Valeant Pharmaceuticals International

(

VRX

), up 5.2%,

Ionis Pharmaceuticals

(

IONS

), up 4.0%,

Biomarin Pharmaceutical

(

BMRN

), up 2.0%,

AstraZeneca

(

AZN

), up 1.2% and

Novo Nordisk A/S

(

NVO

), up 1.1%. A company within the industry that fell today was

Regeneron Pharmaceuticals

(

REGN

), up 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

AbbVie

(

ABBV

) is one of the companies pushing the Drugs industry higher today. As of noon trading, AbbVie is up $0.30 (0.5%) to $59.13 on average volume. Thus far, 3.7 million shares of AbbVie exchanged hands as compared to its average daily volume of 9.0 million shares. The stock has ranged in price between $58.18-$59.81 after having opened the day at $59.08 as compared to the previous trading day's close of $58.83.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $95.4 billion and is part of the health care sector. Shares are down 0.7% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate AbbVie a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

AbbVie

as a

buy

TST Recommends

. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, good cash flow from operations, expanding profit margins and growth in earnings per share. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

AbbVie Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Celgene

(

CELG

) is up $0.57 (0.5%) to $109.38 on light volume. Thus far, 1.6 million shares of Celgene exchanged hands as compared to its average daily volume of 5.3 million shares. The stock has ranged in price between $107.01-$109.84 after having opened the day at $109.01 as compared to the previous trading day's close of $108.81.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $82.9 billion and is part of the health care sector. Shares are down 9.1% year-to-date as of the close of trading on Friday. Currently there are 14 analysts who rate Celgene a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Celgene

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Celgene Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Gilead

(

GILD

) is up $0.98 (1.1%) to $92.81 on light volume. Thus far, 3.1 million shares of Gilead exchanged hands as compared to its average daily volume of 9.6 million shares. The stock has ranged in price between $90.82-$92.91 after having opened the day at $91.52 as compared to the previous trading day's close of $91.83.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical need in North America, South America, Europe, and the Asia-Pacific. Gilead has a market cap of $128.1 billion and is part of the health care sector. Shares are down 9.2% year-to-date as of the close of trading on Friday. Currently there are 11 analysts who rate Gilead a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates

Gilead

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and good cash flow from operations. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Gilead Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).